<DOC>
	<DOC>NCT01386983</DOC>
	<brief_summary>This retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI monotherapy or combination therapy with an alpha-blocker (AB) compared to late initiation of 5ARI therapy in patients receiving combination therapy. The Henry Ford Health System databases will be utilized for this study (2000-2008).</brief_summary>
	<brief_title>Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Males aged 50 years or older medical claim of EP prescription claim(s) for either a 5ARI or both 5ARI and AB (provided both are within 180 days of index date) continuously eligible for 3 months prior to and at least 5 months after their index prescription date. Patients with prostate or bladder cancer any prostaterelated surgical procedure within 5 months of index date prescription claim for finasteride indicative of male pattern baldness; AB monotherapy only; initiation of 5ARI occurring more than 180 days after initiation of AB</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Enlarged prostate, 5-alpha-reductase inhibitor, alpha-blocker, acute urinary retention, surgery, early, costs</keyword>
	<keyword>benign prostatic hyperplasia</keyword>
</DOC>